Product Name: KinSub1RRDSV
Product Number: PE-01AHZ95
Size: 200 µg      Price:99.00
      $US
Peptide Name: KinSub1RRDSV

Product Use: For assaying the phosphotransferase activity of Ribosomal S6 protein-serine kinase 2; Ribosomal protein S6 kinase alpha-3 (RSK2, UniProt ID P51812). The KinSub1RRDSV peptide demonstrated high phosphotransferase activity with Brk, and exhibited moderate specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: KinSub1RRDSV was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.

Peptide Sequence: GGRGRRDSVYNGGHW

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1672.8 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: Brk

Scientific Background: RSK2 is one of several protein kinases that can phosphorylate KinSub1RRDSV. Human RSK2 is a protein-serine/threonine kinase of 740 amino acid length, with a predicted molecular mass of 83,736 Da. It is a member of the AGC group of protein kinases in the RSK family, and RSK subfamily. It is moderate to highly expressed in most tested human tissues. Orthologues of RSK2 are highly conserved in vertebrates and insects. RSK2 is activated by phosphorylation at S227, S369 and T577. Phosphorylation at Y529 induces interaction with ERK1and ERK2, as well as FGFR3. RSK2 forms a complex with either ERK1 or ERK2 in quiescent cells. RSK2 has been shown to mediate growth factor signalling via Ras and MAPK leading to the induction of CREB S133 phosphorylation and activation (1). Mutations in RSK2 have been shown to be responsible for Coffin-Lowry syndrome (CLS) which is a X-linked disorder characterized by severe psychomotor retardation, facial and digital dysmorphisms, and progressive skeletal deformations (2). RSK2 has also been linked with the development of breast carcinomas, gastric adenocarcinomas, and glioblastoma multiforme (GM).